Trial reportRadiation oncology (London, England)2012
Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
Trial report in Radiation oncology (London, England), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review of outcomes following stereotactic ablative radiotherapy in the treatment of early-stage primary lung cancer.The British journal of radiology · 2017Pooled it
- [Comparison of Clinical Outcomes of VATS and SBRT in the Treatment of NSCLC].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2016Pooled it
- Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2014Pooled it
- Correlation of dosimetric factors with the development of symptomatic radiation pneumonitis in stereotactic body radiotherapy.Radiation oncology (London, England) · 2020Trial
- Trial
- Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2017Trial
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.The Lancet. Oncology · 2015Trial
- Changes in volume of stage I non-small-cell lung cancer during stereotactic body radiotherapy.Radiation oncology (London, England) · 2014Trial
- Carbon ion radiotherapy and radiation-induced lung injury: clinical evidence, mechanistic insights, and future directions.Frontiers in oncology · 2026Review
- Immunotherapy-Boosted Stereotactic Ablative Radiotherapy in Inoperable Early-Stage Non-Small Cell Lung Cancer.Current treatment options in oncology · 2025Review
- Prognostic Impact of Tumor Solid Components in Stereotactic Body Radiotherapy for Clinical Stage Tis-1N0M0 Lung Cancer.Thoracic cancer · 2025Article
- Stereotactic body radiotherapy for early‑stage non‑small cell lung cancer: Comprehensive analysis of outcomes and recurrence from a single‑center experience.Oncology letters · 2025Article
- Recent Advances and Current Challenges in Stereotactic Body Radiotherapy for Ultra-Central Lung Tumors.Cancers · 2024Review
- New perspectives on inoperable early-stage lung cancer management: Clinicians, physicists, and biologists unveil strategies and insights.The journal of liquid biopsy · 2024Review
- Radiomics in stereotactic body radiotherapy for non-small cell lung cancer: a systematic review and radiomic quality score study.Radiation oncology journal · 2024Article
- Stereotactic body radiotherapy in lung cancer: a contemporary review.Pathology oncology research : POR · 2024Review
- Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation.Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2024Article
- Volumetric modulated arc therapy (VMAT) comparison to 3D-conformal technique in lung stereotactic ablative radiotherapy (SABR).Journal of medical radiation sciences · 2023Article
- Article
- Identification of novel prognostic factors focusing on clinical outcomes in patients with non-small cell lung cancer after stereotactic body radiotherapy.Oncology letters · 2022Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundStereotactic ablative radiotherapy (SABR) can achieve excellent local control rates in early-stage non-small cell lung cancer (NSCLC) and has emerged as a standard treatment option for patients who cannot undergo surgery or those with isolated recurrences. However, factors that may predict toxicity or survival are largely unknown. We sought here to identify predictors of survival and pneumonitis after SABR for NSCLC in a relatively large single-institution series.
methodsSubjects were 130 patients with stage I NSCLC treated with four-dimensional computed tomography (4D CT) -planned, on-board volumetric image-guided SABR to 50 Gy in 4 fractions. Disease was staged by positron emission tomography/computed tomography (PET/CT) and scans were obtained again at the second follow-up after SABR.
resultsAt a median follow-up time of 26 months, the 2-year local control rate was 98.5%. The median overall survival (OS) time was 60 months, and OS rates were 93.0% at 1 year, 78.2% at 2 years, and 65.3% at 3 years. No patient experienced grade 4-5 toxicity; 15 had radiation pneumonitis (12 [9.3%] grade 2 and 3 [2.3%] grade 3). Performance status, standardized uptake value (SUV)max on staging PET/CT, tumor histology, and disease operability were associated with OS on univariate analysis, but only staging SUV(max) was independently predictive on multivariate analysis (P = 0.034). Dosimetric factors were associated with radiation pneumonitis on univariate analysis, but only mean ipsilateral lung dose ≥ 9.14 Gy was significant on multivariate analysis (P = 0.005).
conclusionsOS and radiation pneumonitis after SABR for stage I NSCLC can be predicted by staging PET SUV(max) and ipsilateral mean lung dose, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.